Skip to main content
  • Cath Lab Recap: Provisional Stenting Bifurcation; Stents for Spasm

    The next-generation CoreValve Evolut PRO got FDA approval for high-risk patients undergoing transcatheter aortic valve replacement, according to an announcement by Medtronic. At last week's American College of Cardiology meeting in Washington, D.C., researchers unveiled a relatively low 11.8% pacemaker rate at 30 days with the device. (MedPage Today)

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details